Reactivating cGAS-STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• NRAS mutations are common in aggressive cancers with poor prognoses.
• Targeted therapies and immune checkpoint inhibitors benefit NRAS wild-type tumors, but NRAS-mutant cancers lack effective treatments.
• NRAS-mutant tumors exhibit a suppressed type I interferon response, correlating with poor outcomes in melanoma.

Purpose of the Study:

• To investigate the impact of NRAS mutations on anti-tumor immunity.
• To identify mechanisms by which NRAS mutations evade immune surveillance.
• To explore therapeutic strategies targeting NRAS-mutant cancers by reactivating innate immune signaling.

Main Methods:

• Analysis of RNA-sequencing data from NRAS-mutant and wild-type tumors.
• Experimental manipulation of NRAS expression (knockdown) to assess cGAS-STING signaling.
• Drug screening to identify compounds that restore immune signaling.
• In vitro and in vivo studies to evaluate combination therapies.

Main Results:

• NRAS-mutant tumors show downregulated type I interferon response and impaired cGAS-STING signaling due to blocked TBK1-STING-IRF3 complex formation.
• Mutant NRAS promotes tumor cell survival and immune evasion by altering cytokine production.
• SOS1 inhibitors reactivate cGAS-STING signaling in NRAS-mutant cells.
• Combination of SOS1 inhibitors and STING agonists enhances anti-tumor immune response.

Conclusions:

• Mutant NRAS actively suppresses anti-tumor immunity by interfering with innate immune signaling pathways.
• Targeting SOS1 and reactivating cGAS-STING signaling presents a promising therapeutic avenue for NRAS-mutant cancers.
• This study provides a mechanistic understanding and a potential treatment strategy for a subset of aggressive cancers.